The Eukaryotic Translation Initiation Factor 4E pipeline drugs market research report outlays comprehensive information on the Eukaryotic Translation Initiation Factor 4E targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Eukaryotic Translation Initiation Factor 4E pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Oncology, Immunology, Cardiovascular, and Central Nervous System which include the indications Melanoma, Multiple Myeloma (Kahler Disease), Psoriasis, Pulmonary Arterial Hypertension, Multiple Sclerosis, and Parkinson’s Disease. It also reviews key players involved in Eukaryotic Translation Initiation Factor 4E targeted therapeutics development with respective active and dormant or discontinued products.
The Eukaryotic Translation Initiation Factor 4E pipeline targets constitutes close to seven molecules. Out of which, approximately six molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase III, and Preclinical stages are 1, and 5 respectively. Similarly, the universities portfolio in Preclinical comprises 1 molecule.
Eukaryotic Translation Initiation Factor 4E overview
Eukaryotic translation initiation factor 4E, also known as eIF4E, is a protein that in humans is encoded by the EIF4E gene, which recognizes the 7-methylguanosine cap structure at the 5′ end of messenger RNAs. The encoded protein aids in translation initiation by recruiting ribosomes to the 5′-cap structure. Association of this protein with the 4F complex is the rate-limiting step in translation initiation. This gene acts as a proto-oncogene, and its expression and activation are associated with transformation and tumorigenesis.
For a complete picture of Eukaryotic Translation Initiation Factor 4E’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
